ME02622B - Pripremanje nalmefen hidrohlorida od naltreksona - Google Patents
Pripremanje nalmefen hidrohlorida od naltreksonaInfo
- Publication number
- ME02622B ME02622B MEP-2016-40A MEP4016A ME02622B ME 02622 B ME02622 B ME 02622B ME P4016 A MEP4016 A ME P4016A ME 02622 B ME02622 B ME 02622B
- Authority
- ME
- Montenegro
- Prior art keywords
- mthf
- phase
- naltrexone
- methyltriphenylphosphonium
- nalmefene
- Prior art date
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title claims 6
- 229960003086 naltrexone Drugs 0.000 title claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims 4
- 238000002360 preparation method Methods 0.000 title claims 3
- 238000000034 method Methods 0.000 claims 17
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000012071 phase Substances 0.000 claims 8
- AZFQCTBZOPUVOW-UHFFFAOYSA-N methyl(triphenyl)phosphanium Chemical class C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 AZFQCTBZOPUVOW-UHFFFAOYSA-N 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 238000002156 mixing Methods 0.000 claims 4
- 239000012074 organic phase Substances 0.000 claims 4
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 3
- 229960005297 nalmefene Drugs 0.000 claims 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 238000007865 diluting Methods 0.000 claims 2
- 150000002576 ketones Chemical class 0.000 claims 2
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical group [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 238000007239 Wittig reaction Methods 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 239000007789 gas Substances 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- QRPRIOOKPZSVFN-UHFFFAOYSA-M methyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 QRPRIOOKPZSVFN-UHFFFAOYSA-M 0.000 claims 1
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 claims 1
- 229960000677 nalmefene hydrochloride Drugs 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (15)
1. Postupak za pripremanje nalmefena od naltreksona Wittig-ovom reakcijom u kojem se 2-metiltetrahidrofuran (MTHF) koristi i u formiranju fosfornog ilida i u naknadnoj reakciji između pomenutog ilida i naltreksona, pri čemu je nalmefen izolovan kao hidrohloridna so nalmefena u jednofaznom postupku bez izolovanja osnove i pripremanja hidrohloridne soli u naknadnoj i odvojenoj fazi.
2. Postupak prema zahtevu 1, koji obuhvata faze a) dobijanje fosfornog ilida umešavanjem metiltrifenilfosfonijumove soli sa MTHF i pogodnom bazom, i b) dodavanje mešavine koja obuhvata naltrekson i MTHF mešavini dobijenoj u fazi a).
3. Postupak prema zahtevu 2, u kojem se faze a) i b) izvode simultano u istoj posudi ili se faze a) i b) izvode sekvencijalno.
4. Postupak prema bilo kom od prethodnih zahteva, u kojem je metiltrifenil fosfonijumova so izabrana između metiltrifenilfosfonijum bromida (MTPPB), metiltrifenilfosfonijum hlorida ili metiltrifenilfosfonijum jodida.
5. Postupak prema bilo kom od prethodnih zahteva, u kojem su pomenuti MTHF i pomenuta metiltrifenilfosfonijum so umešavani u količini (v/w) od 1:1 do 4:1, poželjno 2:1 MTHF u odnosu na pomenutu metiltrifenil fosfonijum so.
6. Postupak prema bilo kom od prethodnih zahteva, u kojem je pomenuta baza koja se dodaje u fazi a) kalijum terc-butoksid (KO-t-Bu).
7. Postupak prema zahtevu 6, gde se pomenuti KO-t-Bu dodaje u ekvimolarnoj količini u odnosu na metiltrifenil fosfonijum so.
8. Postupak prema bilo kom od zahteva 2-7, u kojem se pomenuta mešavina dobijena u fazi a) meša najmanje 1 sat, poželjnije dva sata, pre faze b).
9. Postupak prema bilo kom od zahteva 2-8, u kojem se pomenuti naltrekson koji se koristi u fazi b) dodaje kao anhidrovana čvrsta materija ili kao anhidrovani rastvor u MTHF.
10. Postupak prema zahtevu 9, u kojem je količina pomenutog MTHF u odnosu na naltrekson (v/w) od 2:1 do 6:1, kao što je 3:1 do 5:1 ili 4:1.
11. Postupak za pripremanje nalmefen hidrohlorida prema bilo kom od zahteva 2-10, dalje je okarakterisan izolovanjem proizvoda iz faze b) postupkom koji obuhvata sledeće faze c) (i) mešanje vodenog rastvora koji obuhvata amonijum hlorid (NH4CI) sa mešavinom dobijenom u fazi b), ili (ii) mešanje kiseline ili rastvor koji sadrži neku kiselinu sa mešavinom dobijenom u fazi b), ili (iii) mešanje ketona sa mešavinom dobijenom u fazi b), ili (iv) izvođenje kombinacije gornje faze fazama (i), (ii) i (iii), a zatim (v) opciono razblaživanje mešavine vodom, d) razdvajanje organske faze dobijene u fazi c), e) opciono ispiranje organske faze dobijene u c) vodom i razdvajanje organske faze, f) koncentrovanje organske faze dobijene u fazi d) ili e) pod vakuumom kako bi se uklonile isparljive materije, g) razblaživanje dobijenog ostatka iz faze f) u jednom ili više odgovarajućih organskih rastvarača, h) dodavanje vodonikhlorida (HCI) u mešavinu dobijenu u fazi g), i) izolovanje dobijenog čvrstog ostatka, j) opciono, ponovno suspendovanje čvrste materije iz faze i) jednim ili više odgovarajućih rastvarača i izololovanje čvrstog ostatka, i k) opciono sušenje konačne čvrste materije.
12. Postupak prema zahtevu 11, u kojem je pomenuti organski rastvarač koji se koristi fazi g), i) i/ili fazi j) izabran iz grupe koja obuhvata halogenovane ugljovodonike, alkohole, etre, ketone, estre i aromatične ugljovodonike ili njihove kombinacije kao što je aceton, etil acetat, MTHF, 2-propanol, toluen, dihlorometan ili njihova kombinacija.
13. Postupak prema bilo kom od zahteva 11-12, u kojem se vodonikhlorid (HCl) iz faze h) dodaje kao gas ili kao koncentrovani vodeni rastvor.
14. Postupak prema bilo kom od zahteva 11-13, u kojem se vodonikhlorid (HCl) dodaje u fazi h) pod energičnim mešanjem na temperaturi koja je u opsegu od 0 do 40°C, poželjno 20 do 30°C.
15. Postupak prema bilo kom od zahteva 11-14, u kojem se dobijeni nalmefen HCl transformiše u nalmefen HCl dihidrat rekristalizacijom u vodenom rastvoru.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200900650 | 2009-05-25 | ||
| US18102209P | 2009-05-26 | 2009-05-26 | |
| EP10720257.4A EP2435439B8 (en) | 2009-05-25 | 2010-05-21 | Preparation of nalmefene hydrochloride from naltrexone |
| PCT/DK2010/050110 WO2010136039A1 (en) | 2009-05-25 | 2010-05-21 | Preparation of nalmefene hydrochloride from naltrexone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02622B true ME02622B (me) | 2017-06-20 |
Family
ID=43222172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-40A ME02622B (me) | 2009-05-25 | 2010-05-21 | Pripremanje nalmefen hidrohlorida od naltreksona |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8598352B2 (me) |
| EP (1) | EP2435439B8 (me) |
| JP (1) | JP5794980B2 (me) |
| KR (1) | KR101716522B1 (me) |
| CN (1) | CN102459276B (me) |
| AR (1) | AR076891A1 (me) |
| AU (1) | AU2010252392B2 (me) |
| BR (1) | BRPI1010975B1 (me) |
| CA (1) | CA2763093C (me) |
| CL (1) | CL2011002974A1 (me) |
| CO (1) | CO6470832A2 (me) |
| CR (1) | CR20110612A (me) |
| DK (1) | DK2435439T3 (me) |
| DO (1) | DOP2011000362A (me) |
| EA (1) | EA019331B1 (me) |
| ES (1) | ES2564006T3 (me) |
| GE (1) | GEP20146190B (me) |
| HR (1) | HRP20160110T1 (me) |
| HU (1) | HUE026892T2 (me) |
| IL (1) | IL216422A (me) |
| MA (1) | MA33368B1 (me) |
| ME (1) | ME02622B (me) |
| MX (1) | MX2011012502A (me) |
| MY (1) | MY158251A (me) |
| NZ (1) | NZ596988A (me) |
| PL (1) | PL2435439T3 (me) |
| RS (1) | RS54599B1 (me) |
| SG (1) | SG176205A1 (me) |
| SI (1) | SI2435439T1 (me) |
| SM (1) | SMT201600061B (me) |
| TN (1) | TN2011000590A1 (me) |
| TW (1) | TWI469985B (me) |
| UA (1) | UA106752C2 (me) |
| WO (1) | WO2010136039A1 (me) |
| ZA (1) | ZA201108659B (me) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2580201B1 (en) | 2010-06-11 | 2017-08-02 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
| DK2635586T3 (en) | 2010-11-05 | 2017-03-27 | H Lundbeck As | PROCEDURE FOR THE PREPARATION OF NALTREXON |
| CN103012416B (zh) * | 2011-09-28 | 2015-07-01 | 辽宁海思科制药有限公司 | 一种盐酸纳美芬的制备方法 |
| TWI560170B (en) | 2011-12-06 | 2016-12-01 | Lundbeck & Co As H | Process for recovery of nalmefene hydrochloride |
| CN102584840A (zh) * | 2011-12-28 | 2012-07-18 | 南京优科生物医药有限公司 | 一种制备纳美芬化合物的方法 |
| WO2013164383A1 (en) | 2012-05-03 | 2013-11-07 | H. Lundbeck A/S | Method for the manufacturing of naltrexone |
| US20140005216A1 (en) | 2012-06-27 | 2014-01-02 | H. Lundbeck A/S | Nalmefene for reduction of alcohol consumption in specific target populations |
| CN103204859B (zh) * | 2013-04-25 | 2015-12-02 | 四川海思科制药有限公司 | 一种盐酸纳美芬化合物及其制备方法 |
| AR096851A1 (es) * | 2013-07-11 | 2016-02-03 | H Lundbeck As | Sales que no forman hidratos ni solvatos de nalmefeno |
| JP6448645B2 (ja) | 2013-12-20 | 2019-01-09 | ハー・ルンドベック・アクチエゼルスカベット | メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用 |
| AU2015250611A1 (en) | 2014-04-22 | 2016-11-24 | H. Lundbeck A/S | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| CN104513251A (zh) * | 2014-11-28 | 2015-04-15 | 安徽悦康凯悦制药有限公司 | 一种盐酸纳美芬的制备方法 |
| US9757372B2 (en) * | 2015-03-25 | 2017-09-12 | Taiwanj Pharmaceuticals Co., Ltd. | Toll-like receptor 4 antagonists and use in autoimmune liver diseases |
| RU2712232C1 (ru) * | 2018-10-05 | 2020-01-27 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства | Улучшенный способ получения налмефена из налтрексона |
| US10927121B1 (en) | 2019-12-20 | 2021-02-23 | Southwest Research Institute | Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate |
| JP2023548356A (ja) | 2020-11-02 | 2023-11-16 | ローズ テクノロジーズ | ノルオキシモルホンを精製するための方法 |
| WO2022165040A1 (en) | 2021-01-28 | 2022-08-04 | Rhodes Technologies | Process for crystallizing nalmefene hydrochloride |
| CN117843650A (zh) * | 2023-12-27 | 2024-04-09 | 南京海纳医药科技股份有限公司 | 一种盐酸纳美芬的精制方法 |
| CN117986261B (zh) * | 2024-04-02 | 2024-06-18 | 成都瑞尔医药科技有限公司 | 一种盐酸纳美芬母液的回收套用方法 |
| CN119080788A (zh) * | 2024-08-19 | 2024-12-06 | 南京海鲸药业股份有限公司 | 一种盐酸纳美芬杂质的去除监控系统及去除方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341764A (en) | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
| US4322426A (en) | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
| US4535157A (en) * | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| US4751307A (en) | 1985-01-17 | 1988-06-14 | Mallinckrodt, Inc. | Wittig-reaction processes |
| US4880813A (en) * | 1988-07-22 | 1989-11-14 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for allergic rhinitis |
| US7687646B2 (en) | 2006-03-28 | 2010-03-30 | Azad Pharmaceutical Ingredients, Ag | Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof |
| GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
-
2010
- 2010-05-21 ME MEP-2016-40A patent/ME02622B/me unknown
- 2010-05-21 DK DK10720257.4T patent/DK2435439T3/en active
- 2010-05-21 KR KR1020117028079A patent/KR101716522B1/ko not_active Expired - Fee Related
- 2010-05-21 CA CA2763093A patent/CA2763093C/en active Active
- 2010-05-21 AU AU2010252392A patent/AU2010252392B2/en not_active Ceased
- 2010-05-21 ES ES10720257.4T patent/ES2564006T3/es active Active
- 2010-05-21 MY MYPI2011005679A patent/MY158251A/en unknown
- 2010-05-21 GE GEAP201012510A patent/GEP20146190B/en unknown
- 2010-05-21 UA UAA201114599A patent/UA106752C2/uk unknown
- 2010-05-21 MA MA34465A patent/MA33368B1/fr unknown
- 2010-05-21 EA EA201171461A patent/EA019331B1/ru not_active IP Right Cessation
- 2010-05-21 RS RS20160137A patent/RS54599B1/sr unknown
- 2010-05-21 PL PL10720257T patent/PL2435439T3/pl unknown
- 2010-05-21 MX MX2011012502A patent/MX2011012502A/es active IP Right Grant
- 2010-05-21 SG SG2011086501A patent/SG176205A1/en unknown
- 2010-05-21 BR BRPI1010975-7A patent/BRPI1010975B1/pt not_active IP Right Cessation
- 2010-05-21 HU HUE10720257A patent/HUE026892T2/en unknown
- 2010-05-21 SI SI201031133A patent/SI2435439T1/sl unknown
- 2010-05-21 US US13/321,597 patent/US8598352B2/en not_active Expired - Fee Related
- 2010-05-21 WO PCT/DK2010/050110 patent/WO2010136039A1/en not_active Ceased
- 2010-05-21 JP JP2012512208A patent/JP5794980B2/ja active Active
- 2010-05-21 HR HRP20160110TT patent/HRP20160110T1/hr unknown
- 2010-05-21 NZ NZ596988A patent/NZ596988A/xx not_active IP Right Cessation
- 2010-05-21 CN CN201080033670.3A patent/CN102459276B/zh not_active Expired - Fee Related
- 2010-05-21 EP EP10720257.4A patent/EP2435439B8/en active Active
- 2010-05-24 TW TW99116496A patent/TWI469985B/zh not_active IP Right Cessation
- 2010-05-26 AR ARP100101818A patent/AR076891A1/es unknown
-
2011
- 2011-11-17 IL IL216422A patent/IL216422A/en not_active IP Right Cessation
- 2011-11-21 TN TNP2011000590A patent/TN2011000590A1/en unknown
- 2011-11-22 CR CR20110612A patent/CR20110612A/es unknown
- 2011-11-23 DO DO2011000362A patent/DOP2011000362A/es unknown
- 2011-11-24 CL CL2011002974A patent/CL2011002974A1/es unknown
- 2011-11-24 ZA ZA2011/08659A patent/ZA201108659B/en unknown
- 2011-11-25 CO CO11162008A patent/CO6470832A2/es active IP Right Grant
-
2016
- 2016-02-26 SM SM201600061T patent/SMT201600061B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02622B (me) | Pripremanje nalmefen hidrohlorida od naltreksona | |
| ME02316B (me) | Imidazopiridazini kao inhibitori akt kinaze | |
| JP2012527489A5 (me) | ||
| Ersoy et al. | Mantle source characteristics and melting models for the early-middle Miocene mafic volcanism in Western Anatolia: Implications for enrichment processes of mantle lithosphere and origin of K-rich volcanism in post-collisional settings | |
| UA114497C2 (uk) | Спосіб одержання карбонової кислоти | |
| PT2118090E (pt) | Processo para a preparação de um derivado de benzimidazole | |
| WO2011022811A8 (en) | Recovery of volatile carboxylic acids by a stripper- extractor system | |
| PH12013500030A1 (en) | Method for synthesizing rare earth metal extractant | |
| PH12013500029A1 (en) | Method for synthesizing rare earth metal extractant | |
| RU2020114951A (ru) | Термопластичныe полиоксазолидоны из диизоцианатов и производных диглицидилового эфира 2-фенил-1,3-пропандиола | |
| CN105153258B (zh) | 3-β-羟基-雄甾-17-酮的制备方法 | |
| SI2763948T1 (en) | Procedure for the isolation of an ingenol | |
| JP2015500325A5 (me) | ||
| HRP20170497T1 (hr) | Postupak dobivanja nalmefen hidroklorida | |
| CN102653525A (zh) | 制备苯达莫司汀烷基酯、苯达莫司汀及其衍生物的方法 | |
| CN101698669B (zh) | 一种7-苯乙酰氨基-3-乙烯基-4-对甲氧基苄基头孢菌素的合成方法 | |
| CN116284193B (zh) | 一种分离胆酸和去氧胆酸的方法 | |
| CN106380398A (zh) | 一种溴乙酸叔丁酯的绿色合成方法 | |
| CN104119407A (zh) | 一种甲基-2,3,4-三氧-苄基-β-D-吡喃核糖苷的合成方法 | |
| CA2572607A1 (en) | Epimerisation of allylic alcohols | |
| CN104031003B (zh) | Mbt的复合溶剂精制法 | |
| CN104744238A (zh) | 在苯氧乙酸类农药废水中回收羟基乙酸的方法 | |
| CN103665078A (zh) | 一种17α-羟基甾体酯的制备方法 | |
| MY165642A (en) | Process for preparation of methacrylic acid and methacrylic acid ester | |
| WO2008026219A3 (en) | Novel polymorphs of rimonabant |